1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Drugs In Development, 2022, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hypoparathyroidism - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4 and 2 respectively.
Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hypoparathyroidism - Overview
- Hypoparathyroidism - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Hypoparathyroidism - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hypoparathyroidism - Companies Involved in Therapeutics Development
- Aerami Therapeutics Inc
- Aeterna Zentaris Inc
- Amolyt Pharma
- Ascendis Pharma AS
- BridgeBio Pharma Inc
- Eli Lilly and Co
- Entera Bio Ltd
- Extend Biosciences Inc
- GC Biopharma Corp
- MBX Biosciences Inc
- ProLynx LLC
- Rani Therapeutics LLC
- Hypoparathyroidism - Drug Profiles
- Aerami-701 - Drug Profile
- Product Description
- Mechanism Of Action
- AEZS-150 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AZP-3601 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- encaleret - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- EXT-608 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LY-6272K - Drug Profile
- Product Description
- Mechanism Of Action
- MBX-2109 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- palopegteriparatide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PLX-134 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RT-110 - Drug Profile
- Product Description
- Mechanism Of Action
- Stem cell Therapy - Drug Profile
- Product Description
- Mechanism Of Action
- teriparatide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Hypoparathyroidism - Dormant Projects
- Hypoparathyroidism - Discontinued Products
- Hypoparathyroidism - Product Development Milestones
- Featured News & Press Releases
- Sep 12, 2022: New long-term data in adult patients with hypoparathyroidism treated with Ascendis Pharma’s TransCon PTH through Week 110 in the PaTH forward trial presented at ASBMR 2022
- Aug 31, 2022: Ascendis pharma submits TransCon PTH new drug application to the U.S. FDA for adult patients with hypoparathyroidism
- Jul 26, 2022: MBX Biosciences receives Orphan Drug Designation for lead candidate MBX 2109 for the treatment of hypoparathyroidism
- Jun 14, 2022: Ascendis Pharma announces two oral presentations highlighting the potential for TransCon PTH to be a replacement therapy for adult hypoparathyroidism at ENDO 2022
- Jun 14, 2022: BridgeBio Pharma to present phase 2b data and pivotal phase 3 study design of encaleret in autosomal dominant hypocalcemia type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference
- Jun 13, 2022: BridgeBio Pharma shares positive phase 2b data and announces pivotal study design for phase 3 trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1)
- May 01, 2022: Ascendis Pharma to present TransCon PTH new endocrinology results at Medical Meetings in May
- Mar 13, 2022: Ascendis Pharma announces phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism met primary and all key secondary endpoints
- Mar 02, 2022: Aeterna Zentaris announces notice of allowance for U.S. patent covering AEZS-150 for the potential treatment of chronic hypoparathyroidism
- Nov 18, 2021: Ascendis Pharma announces top-line results from Week 84 of its phase 2 PaTH forward trial demonstrating that TransCon PTH provided durable benefit and was well-tolerated in adults with hypoparathyroidism
- Oct 01, 2021: BridgeBio Pharma announces updated phase 2b data for Encaleret in autosomal dominant hypocalcemia type 1 (ADH1) demonstrating blood and urine calcium normalization in trial participants
- Sep 22, 2021: Ascendis Pharma announces mean bone mineral density (BMD) data from phase 2 PaTH Forward Trial demonstrating continued normalization and stabilization of BMD Z-scores between 26 and 58 weeks
- Jul 06, 2021: Ascendis Pharma announces target enrollment achieved in the Phase 3 PaTHway trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism (HP) and provides a comprehensive global clinical program update
- Jun 03, 2021: The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
- Jun 01, 2021: BridgeBio Pharma receives FDA Fast Track designation for encaleret for the treatment of autosomal dominant hypocalcemia type 1
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Hypoparathyroidism, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hypoparathyroidism - Pipeline by Aerami Therapeutics Inc, 2022
- Hypoparathyroidism - Pipeline by Aeterna Zentaris Inc, 2022
- Hypoparathyroidism - Pipeline by Amolyt Pharma, 2022
- Hypoparathyroidism - Pipeline by Ascendis Pharma AS, 2022
- Hypoparathyroidism - Pipeline by BridgeBio Pharma Inc, 2022
- Hypoparathyroidism - Pipeline by Eli Lilly and Co, 2022
- Hypoparathyroidism - Pipeline by Entera Bio Ltd, 2022
- Hypoparathyroidism - Pipeline by Extend Biosciences Inc, 2022
- Hypoparathyroidism - Pipeline by GC Biopharma Corp, 2022
- Hypoparathyroidism - Pipeline by MBX Biosciences Inc, 2022
- Hypoparathyroidism - Pipeline by ProLynx LLC, 2022
- Hypoparathyroidism - Pipeline by Rani Therapeutics LLC, 2022
- Hypoparathyroidism - Dormant Projects, 2022
- Hypoparathyroidism - Discontinued Products, 2022
- Number of Products under Development for Hypoparathyroidism, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aerami Therapeutics Inc
- Aeterna Zentaris Inc
- Amolyt Pharma
- Ascendis Pharma AS
- BridgeBio Pharma Inc
- Eli Lilly and Co
- Entera Bio Ltd
- Extend Biosciences Inc
- GC Biopharma Corp
- MBX Biosciences Inc
- ProLynx LLC
- Rani Therapeutics LLC
